These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31686592)

  • 21. Genetics of tardive dyskinesia: Promising leads and ways forward.
    Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
    J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.
    Ozdemir V; Basile VS; Masellis M; Kennedy JL
    J Biochem Biophys Methods; 2001 Jan; 47(1-2):151-7. PubMed ID: 11179771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia.
    Lai IC; Liao DL; Bai YM; Lin CC; Yu SC; Chen JY; Wang YC
    Neuropsychobiology; 2002; 46(4):173-5. PubMed ID: 12566932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R
    Can J Psychiatry; 2005 Aug; 50(9):541-7. PubMed ID: 16262110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
    Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
    Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia.
    Matsumoto C; Shinkai T; Hori H; Ohmori O; Nakamura J
    Psychiatry Res; 2004 Jun; 127(1-2):1-7. PubMed ID: 15261699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.
    Wilffert B; Al Hadithy AF; Sing VJ; Matroos G; Hoek HW; van Os J; Bruggeman R; Brouwers JR; van Harten PN
    J Psychopharmacol; 2009 Aug; 23(6):652-9. PubMed ID: 18562401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia.
    Liou YJ; Lai IC; Lin MW; Bai YM; Lin CC; Liao DL; Chen JY; Lin CY; Wang YC
    Pharmacogenet Genomics; 2006 Mar; 16(3):151-7. PubMed ID: 16495774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?
    Koola MM; Tsapakis EM; Wright P; Smith S; Kerwin Rip RW; Nugent KL; Aitchison KJ
    J Psychopharmacol; 2014 Jul; 28(7):665-70. PubMed ID: 24595968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
    Tsai G; Goff DC; Chang RW; Flood J; Baer L; Coyle JT
    Am J Psychiatry; 1998 Sep; 155(9):1207-13. PubMed ID: 9734544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia.
    Chong SA; Tan EC; Tan CH; Mythily ; Chan YH
    Am J Med Genet B Neuropsychiatr Genet; 2003 Jan; 116B(1):51-4. PubMed ID: 12497614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.
    Tsai HT; Caroff SN; Miller DD; McEvoy J; Lieberman JA; North KE; Stroup TS; Sullivan PF
    Am J Med Genet B Neuropsychiatr Genet; 2010 Jan; 153B(1):336-40. PubMed ID: 19475583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver enzyme
    Lu JY; Tiwari AK; Freeman N; Zai GC; Luca V; Müller DJ; Tampakeras M; Herbert D; Emmerson H; Cheema SY; King N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL; Zai CC
    Pharmacogenomics; 2020 Oct; 21(15):1065-1072. PubMed ID: 32969762
    [No Abstract]   [Full Text] [Related]  

  • 34. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients.
    Steen VM; Løvlie R; MacEwan T; McCreadie RG
    Mol Psychiatry; 1997 Mar; 2(2):139-45. PubMed ID: 9106238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations between polymorphisms in the cannabinoid receptor 1 gene, cognitive impairments and tardive dyskinesia in a Chinese population with schizophrenia.
    Lu C; Li S; Li Y; Zhang X; Chi J; Jiang Q; Ma Y; Shi X; Wang L; Li J
    Brain Res; 2023 Dec; 1821():148579. PubMed ID: 37739333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients.
    Zai CC; Tiwari AK; Basile V; De Luca V; Müller DJ; King N; Voineskos AN; Remington G; Meltzer HY; Lieberman JA; Potkin SG; Kennedy JL
    Pharmacogenomics J; 2009 Jun; 9(3):168-74. PubMed ID: 19238168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome wide study of tardive dyskinesia in schizophrenia.
    Lim K; Lam M; Zai C; Tay J; Karlsson N; Deshpande SN; Thelma BK; Ozaki N; Inada T; Sim K; Chong SA; Lencz T; Liu J; Lee J
    Transl Psychiatry; 2021 Jun; 11(1):351. PubMed ID: 34103471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia.
    Hui L; Han M; Yin GZ; Zhang Y; Huang XF; Qian ZK; Gu WG; Gu XC; Zhu XM; Soares JC; Ning Y; Zheng Y; Du XD; Zhang XY
    Schizophr Res; 2017 Apr; 182():104-109. PubMed ID: 27776953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.
    McEvoy J; Park T; Schilling T; Terasawa E; Ayyagari R; Carroll B
    Curr Med Res Opin; 2019 Jul; 35(7):1205-1214. PubMed ID: 30638073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.